From Wikipedia, the free encyclopedia
Jump to: navigation, search
Clinical data
Trade names Revanex[1]
Synonyms YH1885
ATC code
  • None
CAS Number
PubChem CID
Chemical and physical data
Formula C22H23FN4
Molar mass 362.44 g/mol
3D model (JSmol)

Revaprazan (trade name Revanex) is a drug that reduces gastric acid secretion which is used for the treatment of gastritis.[2] It acts as an acid pump antagonist[3] (potassium-competitive acid blocker). Revaprazan is approved for use in Korea,[4] but is not approved in Europe or the United States.


  1. ^ "Revaprazan". 
  2. ^ Kim HK, Park SH, Cheung DY, Cho YS, Kim JI, Kim SS, Chae HS, Kim JK, Chung IS (Oct 2010). "Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects". J Gastroenterol Hepatol. 25 (10): 1618–1625. doi:10.1111/j.1440-1746.2010.06408.x. PMID 20880169. 
  3. ^ Yu KS, Bae KS, Shon JH, Cho JY, Yi SY, Chung JY, Lim HS, Jang IJ, Shin SG, Song KS, Moon BS (Jan 2004). "Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers". J Clin Pharmacol. 44 (1): 73–82. doi:10.1177/0091270003261321. PMID 14681344. 
  4. ^ "Revaprazan Yuhan registered, South Korea (gastritis)". R & D Focus Drug News. September 25, 2006.